Table 2.
Ongoing trials of inotuzumab ozogamicin (INO)
| Reference | Phase | Disease | Intervention | Recruitment |
|---|---|---|---|---|
| NCT03441061 | 2 | B-ALL with positive MRD | INO | Recruiting |
| NCT03677596 | 4 | R/R B-ALL | Investigating lower dose level (1.2 mg/m2/cycle) for those with higher risk for liver toxicity or VOD. | Not yet recruiting |
| NCT03460522 | 2 | Precursor B-cell ALL in 56–74 years old | INO induction followed by conventional chemotherapy | Recruiting |
| NCT02311998 | 1/ 2 | Ph + B-ALL and CML-blast phase | Bosutinib plus INO | Recruiting |
| NCT01925131 | 1 | Acute leukemia of ambiguous lineage, Recurrent Ph + B-ALL, Recurrent Burkitt Lymphoma | INO plus CVP (cyclophosphamide, Vincristine, Prednisone) | Recruiting |
| NCT03739814 | 2 | Ph negative B-ALL | INO followed by Blinatumomab | Recruiting |
| NCT03851081 | 1/ 2 | r/r B-ALL | INO plus Vincristine (liposomal) | Not yet Recruiting |
| NCT01664910 | 1/ 2 | Conditioning regimen for HSCT | INO + plus Rituximab, Bendamustine and Fludarabine | Recruiting |
| NCT03249870 | 2 | Ph negative B-ALL in 55 years or older | INO plus CVP induction | Recruiting |
| NCT03610438 | 2 | ALL with positive MRD prior to HSCT | INO | Not yet recruiting |
| NCT03856216 | 2 | Allogeneic SCT | Pre and Post HSCT INO | Not yet recruiting |
| NCT01371630 | 1/ 2 | Untreated ALL in 60 years and older | INO plus combination chemotherapy | Not yet recruiting |
| NCT03150693 | 3 | Newly diagnosed B-ALL in 18–39 years old | INO plus chemotherapy | Recruiting |
| NCT03094611 | 2 | R/R ALL | Lower dose INO | Recruiting |
| NCT03488225 | 2 | ALL | INO plus HyperCVAD | Recruiting |
| NCT01679119 | 2 | DLBCL | INO plus R-CVP versus Gem-R-CVP |
Recruiting |
| NCT02981628 | 2 | B-ALL in 1–21 years old | INO | Recruiting |
| NCT03628053 | 3 | ALL | Tisagenlecleucel versus Blinatumomab or Inotuzumab | Not yet recruiting |
Abbreviations: R/R refractory /relapsed, CVAD cyclophosphamide vincristine Adriamycin dexamethasone, NHL non-Hodgkin lymphoma, DLBCL diffuse large B cell lymphoma, ALL acute lymphoblastic leukemia, Gem gemcitabine, R rituximab, CVP cyclophosphamide vincristine prednisone, VOD veno-occlusive disease